logo-loader
HealthPharma & Biotech
Zynerba Pharmaceuticals

Zynerba Pharmaceuticals joins Russell 3000 and Russell 2000 indexes

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies

stocks
The Russell 300 Index tracks the performance of 98% of US-traded stocks

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced Monday that it has been added to the Russell 3000 and the Russell 2000 indexes.

The Russell 3000 Index is a market-capitalization-weighted equity index that gives investors exposure to the entire US stock market. The index tracks the performance of the 3,000 largest US-traded stocks, which represent about 98% of all US incorporated equity securities.

The Russell 2000 Index, also market-capitalization-weighted, measures the performance of 2,000 small-cap US companies in the Russell 3000 Index.

READ: Zynerba tells FDA it should regulate CBD and cannabis-derived products like standard pharmaceuticals

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. About $9 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

Zynerba, based in Devon, Pennsylvania, is currently developing Zygel, a CBD gel, to treat children aged three to 17 with Fragile X syndrome. Topline results are expected in the second half of 2019 from a clinical trial that evaluated the gel’s potency and safety. The company also has started a trial to assess how Zygel can treat the pediatric behavioral and emotional symptoms of 22q11.2 Deletion Syndrome.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Zynerba Pharmaceuticals

Price: $11.60

Market: NASDAQ
Market Cap: $269.56 m
Follow

2 min read

;